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Abstract: In this paper we demonstrate, for the first time, the feasibility of a new imaging concept - combined hyper-
polarized 13C-pyruvate magnetic resonance spectroscopic imaging (MRSI) and 18F-FDG-PET imaging. This procedure 
was performed in a clinical PET/MRI scanner with a canine cancer patient. We have named this concept hyper PET. 
Intravenous injection of the hyperpolarized 13C-pyruvate results in an increase of 13C-lactate, 13C-alanine and 13C-
CO2 (
13C-HCO3) resonance peaks relative to the tissue, disease and the metabolic state probed. Accordingly, with 
dynamic nuclear polarization (DNP) and use of 13C-pyruvate it is now possible to directly study the Warburg Effect 
through the rate of conversion of 13C-pyruvate to 13C-lactate. In this study, we combined it with 18F-FDG-PET that stud-
ies uptake of glucose in the cells. A canine cancer patient with a histology verified local recurrence of a liposarcoma 
on the right forepaw was imaged using a combined PET/MR clinical scanner. PET was performed as a single-bed, 
10 min acquisition, 107 min post injection of 310 MBq 18F-FDG. 13C-chemical shift imaging (CSI) was performed just 
after FDG-PET and 30 s post injection of 23 mL hyperpolarized 13C-pyruvate. Peak heights of 13C-pyruvate and 13C-
lactate were quantified using a general linear model. Anatomic 1H-MRI included axial and coronal T1 vibe, coronal 
T2-tse and axial T1-tse with fat saturation following gadolinium injection. In the tumor we found clearly increased 
13C-lactate production, which also corresponded to high 18F-FDG uptake on PET. This is in agreement with the fact 
that glycolysis and production of lactate are increased in tumor cells compared to normal cells. Yet, most interest-
ingly, also in the muscle of the forepaw of the dog high 18F-FDG uptake was observed. This was due to activity in 
these muscles prior to anesthesia, which was not accompanied by a similarly high 13C-lactate production. Accord-
ingly, this clearly demonstrates how the Warburg Effect directly can be demonstrated by hyperpolarized 13C-pyruvate 
MRSI. This was not possible with 18F-FDG-PET imaging due to inability to discriminate between causes of increased 
glucose uptake. We propose that this new concept of simultaneous hyperpolarized 13C-pyruvate MRSI and PET may 
be highly valuable for image-based non-invasive phenotyping of tumors. This methods may be useful for treatment 
planning and therapy monitoring.
Keywords: Cancer, DNP, hyperpolarized, 13C-pyruvate, MR, response monitoring, 18F-FDG-PET, PET/MR, molecular 
imaging
Introduction
Traditionally, staging and anti-cancer therapy 
monitoring has been performed by morphologi-
cal imaging methods. CT imaging applying 
RECIST criteria or similar criteria, has been the 
standard method [1]. Where CT is of less sensi-
tive, e.g. brain and prostate tumors, morpho-
logical proton MRI is largely applied [2, 3]. 
However, recently it has been acknowledged 
that imaging methods visualizing tumor pheno-
type may be of greater value [4, 5]. Especially 
visualization of metabolism, one of the hall-
marks of cancer, has drawn attention as a most 
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powerful tool to characterize solid tumors [6-8]. 
A key metabolic fingerprint in cancer cells is the 
switch to glycolysis with production of lactate 
even in the presence of sufficient oxygen [9-12], 
as illustrated in Figure 1. This phenomenon 
was first described by Heinrich Otto Warburg in 
1924 and has since been named the Warburg 
effect [13, 14]. Since glucose metabolism in 
normal non-hypoxic cells through oxidative 
phosphorylation is much more efficient in ATP 
production than anaerobic glycolysis, higher 
amounts of glucose are utilized in cancer cells 
(10-20 fold) even if these cells do not have a 
higher energy need [4]. This high uptake forms 
the basis for visualizing cancer cells 
and tumors using the glucose ana-
logue 18F-2-fluoro-2-deoxy-D-glucose 
(18F-FDG) [6, 8]. 18F-FDG is transport-
ed into the cells by the same sys-
tems as glucose, i.e. GLUT transport-
ers. However, in contrast to glucose, 
once 18F-FDG is phosphorylated by 
hexokinases it is not further metab-
olized and thus trapped in the cells 
[9, 11]. In agreement with this, it has 
been shown in numerous studies 
that 18F-FDG accumulation corre-
lates with prognosis [15, 16] and 
has proven its value in management 
of many types of cancer patients 
[17]. However, it should be noted 
that 18F-FDG uptake is only an indi-
rect measure of the Warburg Effect. 
Accordingly, non-cancer tissue with 
high glucose consumption and sub-
sequent oxidative phosphorylation 
will also present with high 18F-FDG 
uptake and accumulation, e.g. work-
ing muscles, inflammation, and in 
the highly metabolic active brain. 
Finally, in all cells with high prolifera-
tive rates an increased uptake of 
18F-FDG is seen. 
To further characterize tumors phe-
notypically, methods specifically 
looking at the metabolic pathways 
are of value. Magnetic Resonance 
Spectroscopy (MRS) is a technique 
that offers non-invasive in vivo 
assessment of tissue chemistry and 
cellular metabolism [18]. However, 
the low sensitivity of MRS has large-
ly limited its use for this. Recently, 
Figure 1. Schematic diagram illustrating the Warburg effect and the 
metabolic difference between cancer and normal non-hypoxic cells. 
Normal cells primarily rely on mitochondrial oxidative phosphoryla-
tion to generate the energy needed for the cellular processes. In con-
trast, most cancer cells are switched to aerobic glycolysis, even in the 
presence of oxygen, the Warburg effect. Accordingly in cancer cells 
most glucose when metabolized to pyruvate will be further converted 
into lactate even in the presence of oxygen. Since glucose metabo-
lism in normal non-hypoxic cells through oxidative phosphorylation is 
much more effective than aerobic glycolysis, much higher amounts of 
glucose is utilized in cancer cells (10-20 fold) even if these cells do 
not have a higher energy need.
development of the technique of Dynamic 
Nuclear Polarization (DNP) circumvented this 
elegantly. DNP is capable of creating solutions 
of molecules with polarized nuclear spins in 
various nuclei and has enabled real-time inves-
tigation of in vivo metabolism. The develop-
ment of this new method has enhanced the 
nuclear polarization more than 10,000-fold, 
thereby significantly increasing the sensitivity 
of MRS [19]. Furthermore, the method enables 
measuring the kinetics of the conversion of the 
substrate into other cell metabolites and can 
be combined with anatomical proton MRI. 
Different nuclei have been hyperpolarized 
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using the DNP method. Currently, the most 
widely used nucleus has been 13C due to favor-
ing characteristics and the possibility of incor-
porating 13C into biologically relevant com-
pounds, e.g. pyruvate. Intravenous injection of 
hyperpolarized 13C-pyruvate results in the 
increase of 13C-lactate, 13C-alanine and 13C-CO2 
(13C-HCO3) resonance peaks relative to the tis-
sue, disease and the metabolic state probed 
[19, 20]. Figure 2 illustrates the cell metabo-
lism of 13C-pyruvate. Accordingly, with DNP and 
use of 13C-pyruvate it is now possible to directly 
study the Warburg effect through the rate of 
conversion from 13C-pyruvate to 13C-lactate [21, 
22]. 
The aim of our study was therefore to demon-
strate, for the first time, the feasibility of simul-
taneous in vivo PET combined with hyperpolar-
ized MRI. Specifically, we aimed to show that 
18F-FDG-PET could be combined with 13C- 
pyruvate magnetic resonance spectroscopic 
imaging (MRSI) for characterization of cancer 
using a clinical PET/MRI scanner. 
Methods
A canine cancer patient (female Labrador 
Retriever, 32 kg) with a biopsy-verified local 
recurrence of a liposarcoma on the 
right ante brachium was the test sub-
ject. Imaging was performed using a 
combined PET/MR clinical scanner 
(Siemens mMR Biograph, Siemens, 
Erlangen, Germany). The liposarco-
ma had been irradiated two years 
prior to recurrence (4 fractions) and 
surgically removed. The dog was pre-
medicated with Methadone (0.2 mg/
kg IM) and anaesthetized using a 
bolus injection of Propofol. Anesth- 
esia was maintained by a continuous 
intravenous infusion of Propofol (15-
25 mg/kg/h). Heart rate, oxygen 
saturation, and blood pressure were 
measured throughout the scanning 
procedure. In the periphery of the 
lesion, fish oil capsules were placed 
for better delineation of the tumor on 
the localizers datasets. The dog was 
placed in prone position head-first. 
MRI utilized a dual tuned flex coil 
(RAPID Biomedical, Rimpar, Germa- 
ny). A 5.5 mL vial of 4.0 M 13C-urea 
mixed with Gadolinium (Dotarem, 
Figure 2. Simplistic illustration of the pyruvate cycle showing pyruvate 
converted from glucose through glycolysis. When oxygen is present 
pyruvate is transported to the mitochondria and undergoes oxidative 
phosphorylation with production of ATP, CO2 and H
+. When oxygen is 
depleted (anaerobic glycolysis) or in cancer cells even in presence of 
oxygen (aerobic glycolysis) pyruvate is converted to lactate.
GUERBET, Roissy, France) at the back of the 
coil was used for MR flip angle calibration and 
frequency centering. The coil was placed above 
the front leg and centered on the lesion. 
The study was approved by The Ethics and 
Administrative Committee, Department of Clini- 
cal Veterinary and Animal Sciences, Faculty of 
Health and Medical Sciences, University of 
Copenhagen.
Hyperpolarized 13C-pyruvate
Hyperpolarized 13C-pyruvate was prepared us- 
ing the SpinLab system (GE Healthcare, Mill- 
waukee, WI, USA). The 13C-pyruvate sample 
consisted of [1-13C]pyruvic acid mixed with an 
Electron Paramagnetic Agent (EPA) manufac-
tured by Syncom (Groningen, Netherlands, PN 
AH111501. The EPA concentration in the sam-
ple is 15 mM. The dissolution media applied 
contains 0.1 g/L ethylenediaminetetraacetic 
acid disodium salt dehydrate (EDTA disodium 
salt, Sigma PN E4994) in water. The neutraliza-
tion media used to neutralize the hyperpolar-
ized [1-13C]pyruvic acid sample prior to injection 
contains 0.72 M NaOH, 0.4 M Tris and 0.1 g/L 
EDTA disodium salt in water. 
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1H-MR-imaging
Localizer images and manual 13C flip angle cali-
bration was followed by anatomic 1H-MRI, inclu- 
ding axial T1 vibe and coronal T2-tse. In an axi-
al-oblique 40 mm thick slab including the tumor 
region, dynamic 13C-MRS was performed. Para- 
meters were repetition time (TR) 1,000 ms, 
echo time (TE) 0.757 ms, flip angle 5°, band-
width 4,000 Hz. The acquisition was repeated 
180 times, commencing at the injection of the 
hyperpolarized 13C-pyruvate (23 mL).
18F-FDG imaging
PET was performed as a single-bed, 10 min 
acquisition, 107 min post iv injection of 310 
MBq 18F-FDG. Image reconstruction was per-
formed using 3D OP-OSEM 4i21s, matrix 344, 
4 mm Gaussian post-filter and vendor supplied 
attenuation correction algorithms.
13C-chemical shift imaging 
13C-chemical shift imaging (CSI) was undertak-
en just after 18F-FDG-PET and 30 s post injec-
tion of 23 mL hyperpolarized 13C-pyruvate (250 
mM). Parameters were repetition time 80 ms, 
flip angle 23°, bandwidth 10,000 Hz, FOV 80 
mm, slice thickness 23 mm, matrix 16x16 (cir-
cular truncation) and total imaging time 11 s. 
The 30 s delay was chosen to obtain maximum 
13C-lactate signal during imaging based on the 
previous dynamic 13C-MRS acquisition. Finally, 
axial T1-tse MRI with fat saturation was per-
formed following gadolinium injection (6.4 mL 
Dotarem). Peak heights of 13C-pyruvate, 13C- 
actate, 13C-alanine and 13C-pyruvate hydrate 
were quantified using a general linear model 
implemented in Matlab (MathWorks, Natick, 
MA, USA). A set of additional components were 
included in the model to account for frequency 
shifts and peak splitting of the 13C-pyruvate 
and 13C-lactate peak observed in voxels con-
taining vascular tissue. Further, the first and 
second derivatives of all metabolites were 
included in the model. The estimation was per-
formed in the frequency domain on baseline 
corrected spectra. We report the ratio of 
13C-lactate normalized to the sum of all mod-
eled peak heights.
Results
Work-flow
We found that combined FDG-PET and 13C- 
pyruvate MRSI was feasible in a single session 
of approximately 2 h. A continuous work-flow 
was obtained with start of hyperpolarization of 
13C-pyruvate and injection of FDG-PET almost 
at the same time. After approximately 1½ h a 
Figure 3. Coronal 18F-FDG-PET/MR images of right front leg showing the liposarcoma (arrow). Note the high concen-
tration of 18F-FDG in the muscle. A: 18F-FDG-PET. B: T2_TSE + 18F-FDG-PET. C: T2_TSE. 
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10 min FDG-PET acquisition was performed 
that was immediately followed by dissolution 
and injection of 13C-pyruvate that took less 
than 30 s in our setup. Acquisition of 13C-lactate 
and 13C-pyruvate spectra lasted less than 2 
min. 1H-MR-imaging was performed between 
FDG injection and FDG-PET acquisition.
1H-MRI
The tumor was easily delineated on 1H-MRI as 
clearly seen on the coronal images (Figure 3). 
18F-FDG imaging
On both coronal and transaxial images a high 
uptake of 18F-FDG in the tumor (liposarcoma) 
was observed. Furthermore, also in muscles a 
Initially a dynamic 13C-MRS was performed 
(Figure 5). The dynamic MRS showed a large 
peak 10 s after the injection of the 13C-pyruvate. 
This initial peak was followed by generation of 
13C-lactate, with the peak concentration appe- 
aring approximately 30 to 40 s after 13C-pyruvate 
injection (Figure 5). Comparatively, only very 
low levels of 13C-alalnine were generated (Fi- 
gure 4). For subsequent static CSI a delay of 30 
s was therefore chosen relative to injection of 
13C-pyruvate to obtain imaging at the peak of 
lactate concentration. 13C-pyruvate and 13C- 
lactate CSI are shown in Figure 4D and 4E, 
respectively. We observed high 13C-pyruvate 
concentration in voxels encompassing the large 
vessels adjacent to the muscle corresponding 
to the injected 13C-pyruvate (Figure 4D). In the 
CSI data sets, increased 13C-lactate production 
Figure 4. Transaxial images of right front leg showing the liposarcoma. Note the high concentration of 18F-FDG in 
muscle (arrow, panel B, 18F-FDG-PET + 1H-MRI) and of 13C-pyruvate in the large vessels (arrow in panel D, 13C-Pyru-
vate CSI + 1H-MRI). A: 18F-FDG-PET. B: 18F-FDG-PET + 1H-MRI. C: 1H-MRI. D: 13C-Pyruvate CSI + 1H-MRI. E: 13C-lactate 
CSI + 1H-MRI.
Figure 5. The dynamic 13C-MRS showed initially a large peak 10 s after the injection 
of the 13C-pyruvate. This was followed by generation of 13C-lactate, with the peak con-
centration appearing approximately 40 s after injection.
clear uptake of 18F-F- 
DG was seen (Figures 
3 and 4). Quantifica- 
tion of 18F-FDG uptake 
in the tumor revealed 
a SUVmax of 1.52 the 
transaxial slice where 
13C-chemical shift im- 
aging was performed 
(Figure 4). For muscle 
the SUVmax in the same 
slice was found to be 
almost as high, name-
ly 1.26 (Figure 4). 
13C-chemical shift 
imaging (CSI)
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was observed in the tumor (Figure 4E). 
Calculation of the 13C-lactate/13C-pyruvate ratio 
revealed a ratio of 0.213 in the tumor, 0.078 in 
the muscle and 0.038 in the vasculature) 
(Figure 4). The tumor area with highest 13C- 
lactate/13C-pyruvate ratio also had the highest 
18F-FDG uptake. In Figure 6 13C-MRS of a single 
voxel encompassed in the tumor is shown. Note 
that 13C-lactate and 13C-pyruvate are clearly 
seen as distinct peaks. 
Discussion
To our knowledge this is the first study acquir-
ing both 13C-lactate/13C-pyruvate CSI and 
18F-FDG-PET using a combined clinical PET/MR 
scanner. We found that this new concept, 
hyperPET, simultaneous hyperpolarized 13C-py- 
ruvate MRSI and 18F-FDG-PET, is feasible and 
may be a highly valuable tool for image-based 
non-invasive phenotyping of tumors. In our 
study we were able to visualize in real time the 
in vivo metabolism of 13C-pyruvate and conver-
sion into 13C-lactate in a spontaneous canine 
liposarcoma. In the tumor we found clearly 
13C-lactate production, which also correspond-
ed to high 18F-FDG uptake on PET. This is in 
agreement with the well-know fact that glycoly-
sis and production of lactate are increased in 
tumor cells compared to normal cells [4]. 
However, most interestingly also in the muscle 
of the forepaw of the dog, high 18F-FDG uptake 
was observed due to use of 
these muscles prior to anes-
thesia but this was not accom-
panied by a similarly high 
13C-lactate production. Accor- 
dingly, this clearly demon-
strates how the Warburg effect 
is specifically shown by 13C- 
pyruvate MRSI whereas 18F-
FDG was not capable of this 
and cannot discriminate betw- 
een whether glucose uptake is 
increased due to oxidative 
phosphorylation operating at a 
high level or due to glycolysis. 
In our study, we used a canine 
cancer patient with a sponta-
neous syngeneic cancer as it 
mirrors biological behavior of 
human cancer including het-
erogeneity, microenvironment, 
mode of progression, metasta-
Figure 6. Single 13C-CSI spectrum visualizing the 13C-lactate and 13C-pyru-
vate peaks in a voxel within the liposarcoma.
sis etc.. Accordingly, cancer bearing dogs repre-
sent a unique clinical cancer model with a 
direct potential for facilitating translation of 
results to human patients [23].
Technically, a simple CSI technique was emp- 
loyed for spectroscopic imaging in the current 
study. More advanced techniques allow for 
faster, volumetric and repeated spectroscopic 
imaging (for review, see [24, 25]). Such tech-
niques therefore permit for larger spatial cover-
age and more detailed characterization of the 
tumor metabolism. We aim at implementing 
these techniques in future studies. 
The use of hyperpolarized 13C-pyruvate has pre-
viously in preclinical studies been shown to be 
a sensitive method for diagnosing cancer and 
assessment of early treatment response in a 
variety of cancers [26]. Recently, a first-in-man 
study of 31 patients was conducted with the 
primary objective to assess the safety of hyper-
polarized 13C-pyruvate in healthy subjects and 
prostate cancer patients. The study showed an 
elevated 13C-lactate/13C-pyruvate ratio in 
regions of biopsy-proven prostate cancer [27]. 
With the emergence of hybrid PET/MR systems 
and the present study demonstrating feasibility 
of hyperPET, we therefore suggest that com-
bined 18F-FDG-PET and 13C-pyruvate MRSI 
could be valuable in the clinical work-up of can-
cer patients. MRS imaging with 13C-pyruvate 
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may therefore have clinical relevance as added 
information when used together with 18F-FDG-
PET and provide better phenotyping of tumors. 
In addition, hyperpolarized 13C-pyruvate MRS 
imaging may be the only feasible way to study 
glycolysis in tumors where 18F-FDG-PET is of 
little value as in prostate cancer (low 18F-FDG 
uptake and high bladder activity) and brain 
tumors (high physiological uptake in the brain). 
With regard to early response monitoring in 
cancer treatment, the possibility exists that 
13C-pyruvate can detect such effects earlier 
than 18F-FDG-PET. However, this remains to be 
answered through comparative PET and hyper-
polarized MRSI studies. From both a clinical 
and basic science perspective, further compar-
ison of PET and 13C-pyruvate-lactate conver-
sion is needed to elucidate the differential 
information gained from the modalities. 
Previous preclinical comparison studies have 
been carried out on separate systems [28, 29], 
with a potential error arising from the time dif-
ference between the examinations and errors 
in positioning of the animal. However, the intro-
duction of integrated PET/MR systems allows 
for single-session, simultaneous MRI and PET. 
At present such combined studies with hyper-
polarized MRSI and PET remains to be 
performed. 
With the current study carried out on a canine 
cancer patient with a liposarcoma and using a 
clinical PET/MRI scanner we have clearly dem-
onstrated that concurrent DNP 13C-lactate/13C-
pyruvate CSI and 18F-FDG-PET imaging is feasi-
ble in a clinical setting. Future, systematic 
studies are needed to assess the clinical value 
of combining these modalities within oncology.
Conclusion
To our knowledge this is first study acquiring 
both DNP 13C-lactate/13C-pyruvate CSI and 
18F-FDG-PET using a combined PET/MR scan-
ner. We propose that this new concept of simul-
taneous hyperpolarized 13C-imaging and 
18F-FDG-PET may be highly valuable for image-
based non-invasive phenotyping of tumors. 
Translation into humans of this technique will 
demonstrate whether it is of clinical value.
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